Pfizer Inc. carries a market capitalization of 154.17B, placing it among publicly traded companies globally. Its enterprise value stands at 189.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 154.17B |
| Enterprise Value | 189.04B |
Pfizer Inc. currently has 5.70B shares outstanding.
| Shares Outstanding | 5.70B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Pfizer Inc. trades at a trailing price-to-earnings ratio of 31.63. The price-to-sales ratio is 2.15, and the price-to-book ratio stands at 1.61.
| PE Ratio | 31.63 |
| PS Ratio | 2.15 |
| PB Ratio | 1.61 |
| P/TBV Ratio | -4.12 |
| P/FCF Ratio | 8.69 |
| P/OCF Ratio | 10.22 |
On an enterprise value basis, Pfizer Inc. trades at an EV/EBITDA multiple of 8.01 and an EV/FCF ratio of 10.15. The EV/Sales ratio of 2.97 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.11 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.97 |
| EV / EBITDA | 8.01 |
| EV / EBIT | 11.11 |
| EV / FCF | 10.15 |
Pfizer Inc. maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 73.92, indicating elevated leverage, while an interest coverage ratio of 8.75 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.27 |
| Quick Ratio | 0.85 |
| Debt / Equity | 73.92 |
| Debt / EBITDA | 2.68 |
| Interest Coverage | 8.75 |
| Return on Equity (ROE) | 4.98 |
| Return on Assets (ROA) | 2.13 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 5.90 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.58 |
Over the trailing twelve months, Pfizer Inc. has paid -164.00M in income taxes, reflecting an effective tax rate of 14.54.
| Income Tax | -164.00M |
| Effective Tax Rate | 14.54 |
Pfizer Inc.'s stock has gained approximately 10.04882% over the past 52 weeks. The 50-day moving average sits at 25.09, while the 200-day moving average is 25.88.
| Beta (5Y) | N/A |
| 52-Week Price Change | 10.04882% |
| 50-Day Moving Average | 25.09 |
| 200-Day Moving Average | 25.88 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Pfizer Inc. generated 63.70B in revenue and converted that into 4.33B in net income, yielding earnings per share of 0.77. EBITDA reached 23.60B, while operating income came in at 17.02B.
| Revenue | 63.70B |
| Gross Profit | 46.61B |
| Operating Income | 17.02B |
| Pretax Income | 4.21B |
| Net Income | 4.33B |
| EBITDA | 23.60B |
| EBIT | 17.02B |
| Earnings Per Share (EPS) | 0.77 |
Pfizer Inc. holds 11.70B in cash and equivalents against 63.19B in total debt, resulting in a net debt position of 62.22B. Total book value stands at 85.19B, with working capital of 8.71B providing operational flexibility.
| Cash & Cash Equivalents | 11.70B |
| Total Debt | 63.19B |
| Net Debt | 62.22B |
| Equity (Book Value) | 85.19B |
| Book Value Per Share | 14.95 |
| Working Capital | 8.71B |
Pfizer Inc. produced 13.40B in operating cash flow over the past twelve months. After subtracting -2.42B in capital expenditures, free cash flow totaled 10.99B - equivalent to 1.93 per share.
| Operating Cash Flow | 13.40B |
| Capital Expenditures | -2.42B |
| Free Cash Flow | 10.99B |
| FCF Per Share | 1.93 |
Pfizer Inc. operates with a gross margin of 73.18, reflecting its pricing power and cost economics. The operating margin of 26.72 and net profit margin of 6.80 provide insight into operational efficiency.
| Gross Margin | 73.18 |
| Operating Margin | 26.72 |
| Pretax Margin | 6.61 |
| Profit Margin | 6.80 |
| EBITDA Margin | 37.06 |
The company's payout ratio of 221.98 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1.72 |
| Dividend Yield | N/A |
| Payout Ratio | 221.98 |
| Shareholder Yield | 6.12 |
| FCF Yield | 11.51 |
Pfizer Inc.'s most recent stock split took place on November 17, 2020 with a 500:527 split ratio.
| Last Split Date | 11/17/2020 |
| Split Ratio | 500:527 |
Pfizer Inc. posts an Altman Z-Score of 4.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.19 |